Last updated on May 2020

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Brief description of study

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Detailed Study Description

25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16.

At week 16, patients with remaining BSA 3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have 3% BSA at week 16 will remain on Ilumya monotherapy.

Patients will continue to be evaluated at weeks 20 and 24.

Clinical Study Identifier: NCT04347473

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.